Retatrutide Side Effects and Safety: What the Phase 3 Data Actually Shows (2026)

Retatrutide is the most powerful weight-loss drug in late-stage testing, but it is also one of the most misunderstood. It is still investigational. It is not FDA-approved, it cannot be legally prescribed for weight loss in 2026, and anything sold online as "retatrutide" is an unapproved research chemical with no quality guarantees. This guide covers what the actual clinical trial data says about retatrutide side effects, who they affect, how they compare to existing GLP-1 medications, and the safety signals worth understanding before the drug ever reaches the market.

The short answer

Retatrutide's side effect profile looks a lot like other incretin drugs, just turned up. The most common problems are gastrointestinal: nausea, diarrhea, constipation, and vomiting. These are dose-dependent, usually worst during dose escalation, and tend to ease over time. The drug also carries one signal that sets it apart from semaglutide and tirzepatide: dysesthesia, a tingling or altered skin sensation, which showed up far more often at the highest dose.

In the first completed Phase 3 trial, about 1 in 8 people on the 9 mg dose and nearly 1 in 5 on the 12 mg dose stopped treatment because of side effects. That is meaningfully higher than placebo and higher than what is typical for approved GLP-1 drugs, which is the tradeoff that comes with retatrutide's larger weight-loss numbers.

What retatrutide is

Retatrutide (development code LY3437943) is a once-weekly injectable being developed by Eli Lilly. It is a first-in-class triple hormone receptor agonist, meaning it activates three targets at once: GIP, GLP-1, and glucagon. Semaglutide (Wegovy, Ozempic) hits one of those receptors. Tirzepatide (Zepbound, Mounjaro) hits two. Retatrutide adds the glucagon receptor, which is thought to increase energy expenditure on top of appetite suppression.

That third target is the source of both its strength and several of its safety questions.

The Phase 3 safety data (TRIUMPH-4)

In late 2025, Lilly reported the first Phase 3 results, from the TRIUMPH-4 trial in adults with obesity or overweight plus knee osteoarthritis. At 68 weeks, the 12 mg dose produced an average weight loss of 28.7%, about 71.2 lbs, using the efficacy estimand. The 9 mg dose produced 26.4%. Placebo was 2.1%.

Here is what the safety side looked like. The percentages below are for the 9 mg and 12 mg doses compared to placebo:

• Nausea: 38.1% and 43.2%, versus 10.7% on placebo
• Diarrhea: 34.7% and 33.1%, versus 13.4%
• Constipation: 21.8% and 25.0%, versus 8.7%
• Vomiting: 20.4% and 20.9%, versus 0.0%
• Decreased appetite: 19.0% and 18.2%, versus 9.4%

• Dysesthesia: 8.8% and 20.9%, versus 0.7%

Discontinuation due to adverse events was 12.2% on 9 mg and 18.2% on 12 mg, versus 4.0% on placebo. Lilly described the dysesthesia events as generally mild and rarely leading to people stopping the drug.

It is worth being precise about what this trial was. TRIUMPH-4 studied the two highest doses in a population that was heavily weighted toward severe obesity, with 84% of participants at a BMI of 35 or above. The broader obesity trial, TRIUMPH-1, and six other Phase 3 readouts are expected through 2026, and those will fill in the picture for lower doses and a more general population.

Gastrointestinal side effects

The GI effects are the headline issue and the main reason people stop. They are driven by how the drug slows stomach emptying and acts on appetite and gut signaling. A few patterns hold up across the data:

They are dose-dependent. Higher doses mean more nausea and vomiting. This is why every incretin drug, retatrutide included, is started low and titrated up slowly.

They are front-loaded. Most GI complaints cluster around dose increases and the first weeks at a new dose, then settle as the body adapts.

They are mostly manageable. The standard playbook for GLP-1 nausea applies: smaller meals, eating slowly, avoiding high-fat and greasy foods, staying hydrated, and not rushing dose increases. Our GLP-1 side effects management guide breaks down practical strategies for each symptom.

The concern with retatrutide specifically is magnitude. A nausea rate above 40% at the top dose is higher than the rates typically reported for semaglutide and tirzepatide, so the same management tactics may need to be applied more aggressively, and slower titration may matter more.

Dysesthesia: the retatrutide-specific signal

Dysesthesia, an abnormal skin sensation often described as tingling, prickling, or heightened sensitivity to touch, is the side effect that distinguishes retatrutide from the GLP-1 drugs people already know. In TRIUMPH-4 it occurred in 20.9% of people on the 12 mg dose, compared to under 1% on placebo, and it scaled sharply with dose.

This signal also appeared in retatrutide's earlier Phase 2 trial, where it was described as a cutaneous hyperesthesia that was generally mild and reversible. It has not been linked to lasting nerve damage in the trial data so far, and it rarely caused people to quit. Still, it is a real and dose-related effect that anyone evaluating retatrutide should know about, and it is one of the things regulators will scrutinize closely.

Heart rate, blood pressure, and cardiovascular markers

Like other incretin drugs, retatrutide raises heart rate modestly. In the Phase 2 program this was dose-dependent and tended to peak partway through treatment before easing. A resting heart rate increase is a class effect for this drug family and is something prescribers monitor.

The picture is not all negative on the cardiovascular side. In TRIUMPH-4, retatrutide lowered systolic blood pressure by up to 14.0 mmHg at the highest dose and reduced markers of cardiovascular risk including non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein. The weight loss itself drives much of this benefit. The net cardiovascular effect will become clearer as longer trials with outcome data report out.

The glucagon question

Retatrutide's glucagon activity is what enables its larger weight loss, but glucagon also raises blood sugar. In early dose-finding work, the highest doses showed small, mostly transient increases in glucose and in HbA1c in some participants before the drug's overall metabolic benefits took over. In people with diabetes this is something trials are watching carefully, and it is one reason the dedicated type 2 diabetes trials matter. For people without diabetes, the trial data has not flagged this as a major clinical problem, but it remains an area under active study.

Class warnings to expect

Based on how other incretin drugs are labeled, retatrutide is likely to carry a boxed warning about thyroid C-cell tumors, which is a class warning derived from rodent studies. GLP-1 and dual-agonist drugs also carry warnings and precautions around pancreatitis, gallbladder disease, kidney injury from dehydration during severe vomiting or diarrhea, and a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN 2. There is no reason to expect retatrutide to be exempt from these, and its final FDA label will define them precisely.

Why "retatrutide" sold online is a separate safety problem

Because retatrutide is not approved, it is not available from a pharmacy, a telehealth provider, or a compounding facility for weight loss. Any product marketed online as retatrutide is an unregulated research chemical. There is no verified purity, no guaranteed dose accuracy, no sterility assurance, and no medical oversight. The trial safety data in this guide describes pharmaceutical-grade retatrutide given under close monitoring with careful dose titration. None of that applies to a vial bought from a gray-market vendor, and the risks of an unverified injectable are entirely separate from, and on top of, the drug's known side effects. If you are weighing compounded versus brand-name options that are actually legal today, our compounded vs brand GLP-1 guide explains where the real lines are.

How retatrutide compares on safety

The fair summary is that retatrutide trades a heavier side effect burden for larger weight loss. Its GI rates and its discontinuation-for-side-effects rate run higher than what approved GLP-1 drugs typically show, and it adds the dysesthesia signal that those drugs do not have. That does not make it unsafe in a trial setting, where it is titrated and monitored, but it does mean it is not simply a stronger, free-lunch version of what already exists. For most people choosing a weight-loss medication in 2026, the relevant comparison is between the approved options, which our beginner's guide to GLP-1 peptides walks through.

Frequently asked questions

Is retatrutide safe? In its Phase 3 and Phase 2 trials, retatrutide's side effects were consistent with the incretin drug class, just at higher rates, with most being gastrointestinal and dose-related. It has not yet completed its full Phase 3 program or received FDA review, so its complete safety profile is not finalized. It is also not available legally for weight loss, so any real-world "retatrutide" carries the added, separate risks of an unregulated product.

What is the most common retatrutide side effect? Nausea, reported by roughly 38% to 43% of people at the higher doses in Phase 3, followed by diarrhea, constipation, and vomiting. These are usually worst during dose increases and tend to improve over time.

What is dysesthesia and should I worry about it? Dysesthesia is an altered skin sensation such as tingling or heightened sensitivity. It appeared in about 1 in 5 people on the top retatrutide dose, was generally mild and reversible in the trials, and rarely caused people to stop. It is the side effect most specific to retatrutide.

Is retatrutide more dangerous than Ozempic or Zepbound? It is not approved, so a direct safety comparison is not settled. The trial data shows higher GI side effect rates and a higher discontinuation rate than is typical for approved GLP-1 drugs, plus the dysesthesia signal. It also produces larger weight loss. The tradeoff, not a simple "safer or more dangerous," is the accurate framing.

When will retatrutide be available? Lilly expects seven additional Phase 3 readouts through 2026, after which the drug would need FDA review before any approval. As of 2026 it is not available by prescription for weight loss.

The bottom line

Retatrutide's safety story is a tradeoff. It delivers the largest weight loss seen in this drug class, and it does so with a heavier and dose-dependent side effect load, dominated by gastrointestinal symptoms and accompanied by a distinctive dysesthesia signal. The trial data is encouraging on efficacy and cardiovascular markers and reassuring that the worst side effects are mostly manageable and reversible, but the drug is still investigational, its full Phase 3 program is not complete, and it is not something you can or should obtain outside of a trial in 2026. Watch the TRIUMPH readouts this year for the clearest picture yet.

Sources

• Eli Lilly and Company, TRIUMPH-4 Phase 3 topline results press release, December 2025 (investor.lilly.com)
• Jastreboff et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity," New England Journal of Medicine, 2023 (Phase 2)
• ClinicalTrials.gov, retatrutide TRIUMPH program study records